Neither case in which RHOA (patient 7) or IDH2 (patient 4) variants persisted in the ctDNA after treatment attained a lasting CMR, in keeping with their likely presence within AITL cells. This evidence concerns the gene IDH2 and angioimmunoblastic T-cell lymphoma.